Zevra Therapeutics Inc. (ZVRA) - Total Assets
Based on the latest financial reports, Zevra Therapeutics Inc. (ZVRA) holds total assets worth $270.12 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore ZVRA debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Zevra Therapeutics Inc. - Total Assets Trend (2012–2024)
This chart illustrates how Zevra Therapeutics Inc.'s total assets have evolved over time, based on quarterly financial data. See Zevra Therapeutics Inc. net assets for net asset value and shareholders' equity analysis.
Zevra Therapeutics Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Zevra Therapeutics Inc.'s total assets of $270.12 Million consist of 48.3% current assets and 51.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 19.0% |
| Accounts Receivable | $10.51 Million | 5.9% |
| Inventory | $1.97 Million | 1.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $68.99 Million | 38.7% |
| Goodwill | $4.70 Million | 2.6% |
Asset Composition Trend (2012–2024)
This chart illustrates how Zevra Therapeutics Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Zevra Therapeutics Inc. (ZVRA) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zevra Therapeutics Inc.'s current assets represent 48.3% of total assets in 2024, a decrease from 89.0% in 2012.
- Cash Position: Cash and equivalents constituted 19.0% of total assets in 2024, down from 86.7% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 40.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 38.7% of total assets.
Zevra Therapeutics Inc. Competitors by Total Assets
Key competitors of Zevra Therapeutics Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
|
Sk Biopharmaceuticals Co Ltd
KO:326030
|
Korea | ₩1.20 Trillion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
Zevra Therapeutics Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.62 | 2.88 | 1.11 |
| Quick Ratio | 8.57 | 2.63 | 1.10 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $199.00 Million | $64.96 Million | $846.00K |
Zevra Therapeutics Inc. - Advanced Valuation Insights
This section examines the relationship between Zevra Therapeutics Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.88 |
| Latest Market Cap to Assets Ratio | 2.90 |
| Asset Growth Rate (YoY) | 3.4% |
| Total Assets | $178.13 Million |
| Market Capitalization | $516.25 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Zevra Therapeutics Inc.'s assets at a significant premium (2.90x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Zevra Therapeutics Inc.'s assets grew by 3.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Zevra Therapeutics Inc. (2012–2024)
The table below shows the annual total assets of Zevra Therapeutics Inc. from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $178.13 Million | +3.37% |
| 2023-12-31 | $172.33 Million | +49.41% |
| 2022-12-31 | $115.34 Million | -13.24% |
| 2021-12-31 | $132.94 Million | +1086.02% |
| 2020-12-31 | $11.21 Million | +6.68% |
| 2019-12-31 | $10.51 Million | -60.72% |
| 2018-12-31 | $26.75 Million | -49.01% |
| 2017-12-31 | $52.46 Million | -38.20% |
| 2016-12-31 | $84.89 Million | +52.34% |
| 2015-12-31 | $55.72 Million | +306.33% |
| 2014-12-31 | $13.71 Million | +464.59% |
| 2013-12-31 | $2.43 Million | -17.16% |
| 2012-12-31 | $2.93 Million | -- |
About Zevra Therapeutics Inc.
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under P… Read more